*Vanderbilt University Medical Center
¶Department of Veterans Affairs, Nashville, TN
†University of Arizona, Tucson, AZ
‡Pfizer Oncology, La Jolla, CA
§Washington University School of Medicine, St. Louis, MO
∥Johns Hopkins University, Baltimore, MD
Conflicts of interest: Emily Chan: Member of advisory boards for Bristol-Myers Squibb, Imclone, and Pfizer; research funds from Pfizer. Jordan D. Berlin: Member of advisory boards for Bristol-Myers Squibb, Imclone, and Pfizer; research funds from Pfizer, Bristol-Myers Squibb, and Imclone. Mace L. Rothenberg: Leadership position at Pfizer Oncology; at the time of conducting this research, he was a Professor at Vanderbilt and had no financial conflict with Pfizer. Christine H. Chung: Research funds from Bristol-Myers Squibb, Amgen, Merck, and AstraZeneca.
The other authors declare no conflicts of interest.
Dr Robert Coffey was supported by Grant Numbers P50CA095103 and CA46413 from National Cancer Institute. This study was also supported with funding from Bristol-Myers Squibb.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI or NIH.
Cetuximab was supplied by Bristol-Myers Squibb and Imclone.
Celecoxib was supplied by Pfizer.
Reprints: Emily Chan, MD, PhD, Vanderbilt-Ingram Cancer Center, 777 Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232. e-mail: [email protected].
